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Abstract
Background: Malaria intermittent preventive treatment of malaria in infant with sulphadoxine-pyrimethamine (IPTi-
SP) reduced the incidence of malaria and anaemia by 30% and 20% respectively. The strategy is now a
recommended policy for malaria control. However, there was no published study on the impact of the strategy on
mortality. The present study assessed the impact of the implementation of IPTi-SP in health services in Mali on all-
cause mortality.
Methods: The 22 health sub-districts of the district of Kolokani were randomized at a 1:1 ratio to either receive
IPTi-SP or to serve as a control. The IPTi-SP was implemented for two years starting December 2006. Information
on births and deaths through 31 March, 2009 was collected on all children who reached four months of age on
1 December, 2006, likely to be exposed to the intervention in 75 localities randomly selected in each zone.
Results: A total of 5,882 children (2,869 from the intervention zone and 3,013 from the nonintervention zone) who
reached four months of age between 1 December, 2006 and 1 December, 2008 were surveyed between the age
of four months to the age of 18 months from 1 December, 2006 to 31 March, 2009. In the cohort of four to 18
months of age, the mortality rate per 1,000 children was 2.53 in the intervention zone compared to 3.46 in the
nonintervention zone, gender and season adjusted mortality rate ratio (MRR) = 0.73 (95% CI 0.55-0.97, p = 0.029). In
the cohort of the four to 12 months of age, mortality rates per 1,000 children were 2.22 in the intervention zone
and 3.13 in the non-intervention zone, MRR = 0.71 (95% CI 0.49-1.02, p = 0.064) adjusted for gender and season.
Conclusion: The implementation of the IPTi-SP resulted in a substantial reduction in all-cause mortality in children.
The results of this study support the adoption and the implementation of IPTi-SP as malaria control strategy.
Trial Registration: ClinicalTrials.govNCT00766662
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It is estimated that about one million of people in sub-
Saharan Africa died directly from malaria in 2008, of
which 800,000 were children under five years [1]. The
numbers are higher if indirect contribution of malaria is
taken into account [2,3]. In the absence of licensed vac-
cine against malaria, intermittent preventive treatment of
malaria in infants (IPTi) consisting of the administration
of a curative dose of sulphadoxine-pyrimethamine (SP) at
the time of EPI vaccination (DTP2, DTP3 and measles
vaccine) regardless of the presence of symptoms or infec-
tion was developed to reduce the burden of malaria. Ran-
domized control studies have shown that the strategy
reduced the incidence of malaria by 30% and the inci-
dence of anaemia by 20% [4]. The strategy is now recom-
mended as policy for malaria control in infants in areas
of moderate or high malaria transmission and where the
r e s i s t a n c et oS Pi sl o w[ 5 ] .H o w e v e r ,t h e r ew a sn op u b -
lished study on the impact of the strategy on the mortal-
ity. The sample size and the duration of follow-up of
initial studies, which assessed the efficacy of the strategy
on the clinical episodes, did not allow the assessment of
its efficacy on mortality. The pilot implementation of
IPTi in health services in Mali offered an opportunity to
address this question. The objective of the present study
was to assess the impact of IPTi implementation in
health services in Mali on the mortality in the targeted
population.
Methods
Study site
The study was conducted in the district of Kolokani,
Mali. The district covers 14,380 km
2, divided into 22
health sub-districts. Each health sub-district covers sev-
eral villages (average of 13 villages/health sub-district).
The total population was 208,317 inhabitants with chil-
dren under one year of age representing about 4% of the
total population. Malaria is hyperendemic in the region
with parasite prevalence in children under five years of
45% during the dry season and above 70% during the
rainy season [6]. Each sub-district was managed by a phy-
sician or a nurse assisted by other nurses. The district
hospital located in Kolokani is the reference centre for
the 22 heath sub-districts. A team composed of physi-
cians, midwives, nurses and managers ensure the activ-
ities at the district heath centre and the coordination and
supervision of the activities in the health sub-districts.
Study participants and design
The study was a cluster randomized trial. The 22 health
sub-districts were randomized in a 1:1 ratio with the
intervention in 11 health areas and the other 11 serving
as controls for the assessment of the impact of IPTi
implementation on the mortality. The intervention con-
sisted of the administration of a half tablet of SP along
with EPI vaccines: second and third dose of the DTP at
the age of three and four months respectively and
m e a s l e sa n dy e l l o wf e v e rv a c c i n e sa tn i n em o n t h so f
age. The implementation started in December 2006
after the training of the health personnel and provision
of SP to the health centres. This implementation was
co-supervised by the Malaria Research and Training
Center (MRTC) of the University of Bamako and the
district health services through December 2007. The
implementation continued in the intervention zones
through December 2008 under the supervision of the
health services. Sulphadoxine-pyrimethamine used dur-
ing the second year was provided by UNICEF to the dis-
trict health services. A cross-sectional survey conducted
after one year of the implementation in December 2007
found that 77% of children who received the EPI vac-
cines also received the IPTi-SP in the intervention zone
while this proportion was less than 3% in the non-inter-
vention zone [7]. The impact of the implementation on
all-cause mortality was assessed in April 2009 using a
cross-sectional survey. UNICEF was not involved with
this evaluation of the effect on mortality.
Sample size and sampling
Using an approximation of arc-sinus transform formula,
assuming an expected mortality rate of 106 for 1,000 per-
son-months in children aged four to 18 months, to detect
a 30% difference in mortality between the two zones with
an alpha error of 5% and a power of 80%, about 1,263 sub-
jects in each zone were needed if a simple random sam-
pling method was used. Assuming a cluster effect of 1.5,
taking into account the cluster sampling and a proportion
of missing data of 5%, a total of 1,995 subjects per zone
were needed. With a total population estimated at 214,509
inhabitants and a proportion of children aged four to 18
months of 4% (8,580) about half the total population (i.e.
half the localities in the district) was to be surveyed.
A total of 150 localities were randomly selected and
each household was visited. A simple questionnaire was
designed and used collect information in all the chil-
dren, who reached age of four months between 1
December, 2006 and 1 December, 2008 (born between 1
August, 2006 and 1 August, 2008) likely to be exposed
to the intervention between 1 December, 2006 and 31
December, 2008. Data were collected by interview and
using the child’s birth certificate, vaccination card or
mother antenatal consultation records. Information col-
lected include the locality, the sub-district, the com-
pound, the household number and subject number in
the household, date of birth, vital status (died or not)
and date of death if applicable.
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Data were collected on forms, were transferred in
Bamako and double entered using Microsoft Access and
reconciled. Statistical analysis was performed using Stata,
version 10 (Houston Texas, USA). The primary endpoint
was the all-cause mortality between 1 December, 2006
and 31 March, 2009 in children aged four to18 months
(cohort 1). The secondary endpoint was the all-cause
death rate between 1 December, 2006 and 31 March,
2009 in children aged four to 12 months (cohort 2).
Cohort 2 was included in cohort 1. The death rates in the
two zones were compared using Fischer exact test. Cox
regression model adjusted for gender and stratified by tri-
mester was used to adjust for the potential effect of the
transmission season and gender. The starting point was
the date of age of four months (to start the exposition to
the intervention) and the ending point was either: i) the
date of age of 18 months or 12 months for cohort 1 and
cohort 2 respectively, or ii) date of death, or iii) 31
March, 2009. The duration of follow-up (period at risk)
for each subject was the number of days between the
starting and the ending points.
Ethical considerations
Initial and successive amendments of the protocol were
examined and approved by the Ethical Committee of the
Faculty of Medicine, Pharmacy and Dentistry of the Uni-
versity of Bamako. Informed consents were obtained
from parents prior to interview.
Results
A total of 5,882 children that reached four months of age
between 1 December, 2006 and 1 December, 2008 in the
study area were surveyed, including 2,869 from 75 local-
ities in the intervention zone and 3,013 from 75 villages in
the non-intervention zone. The gender distribution was
similar between the two zones (50.5% in the intervention
zone and 51.6% in the non-intervention zone were male,
p = 0.43). The exact date of death was unknown for two
subjects (a boy in the intervention zone born on 15 Febru-
ary, 2007 and a girl born on 10 January 2008, in the non-
intervention zone) who were excluded from the analysis.
Among the 5,880 children, 198 died at the age of four
to 18 months and 119 died at the age of four to 12
months. Of the children who died at age of four to 18
months, 86 (2.86%) lived in the intervention and 112
(3.91%) lived in the non-intervention zone (Fischer exact
test; two sided p-value p = 0.030). Of those who died at
the age of four to 12 months, 51 (1.69%) lived in the
intervention zone and 68 (2.37%) lived in the non-inter-
vention zone (Fischer exact test; two sided p-value p =
0.078). The mortality rate, mortality rates ratios and
reduction in mortality are presented in Table 1. In the
cohort of four to 18 months of age, the mortality rate per
1,000 children was 2.532 in the intervention zone com-
pared to 3.456 in the nonintervention zone, gender-
adjusted mortality rates ratio (MRR) = 0.73 (95% CI 0.55-
0.97, p = 0.029). In the cohort of the four to 12 months
of age, mortality rates per 1,000 children were 2.223 in
the intervention zone and 3.126 in the non-intervention
zone, adjusted for gender of MRR = 0.71 (95% CI 0.49-
1.02, p = 0.64). The curves of the Kaplan-Meier survival
estimates of time to death in children from four months
shows significant difference in survival between the two
zones (p <0.001) (Figure 1)
Discussion
This study estimated the effect of two years of IPTi imple-
mentation on mortality in children and has found a reduc-
tion in all-cause mortality by 27% and 29% in children
four to 18 months of age and those of four to 12 months
of age, respectively. Use of insecticide-impregnated bet
nets (ITN) for malaria control in endemic areas was asso-
ciated with a reduction of 17% in all-cause mortality [8].
The implantation of IPTi along with EPI resulted in a
reduction in all-cause mortality greater than the reduction
provided by ITN, a current recommended strategy for
malaria control.
Demonstrating the effect of a malaria control strategy on
malaria specific mortality has always been difficult due to
the requirement of large sample size and factors that can
confound the relationship between the intervention and
the malaria-specific mortality. For example, the impact of
the use of the ITN on malaria-specific mortality could not
be demonstrated initially in individual, large, randomized
control trials [9,10], but only in the meta-analysis studies
[8,11]. Attributing a death to malaria is difficult as the
current indirect methods, such as verbal autopsies, lack
sensitivity and specificity [12]. The effect of a malaria
intervention on all-cause mortality was reported in pre-
vious studies [9,13,19]. Although, it requires a larger num-
ber of subjects than malaria-specific mortality assessment,
there is no issue of sensitivity or the specificity when asses-
sing it. For these reasons, the objective of the present
study was limited to the assessment of the impact of the
IPTi implementation on all-cause mortality. Additional
reason for focusing on this objective was the fact that the
data were collected retrospectively and far from the events,
which made it difficult to accurately assign the cause of
the death (including when verbal autopsy methods were
used).
In the present study, the reduction in all-cause mortal-
ity may be due to a combination of both the direct and
indirect effect of the IPTi on malaria and the indirect
effects on other causes of death. Previous evaluations
have shown that the implementation of IPTi has resulted
in a significant increase in coverage of EPI vaccines, an
increase that was more marked in the intervention zone
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vention zone may have contributed to the increase in
child survival in these areas. Previous studies have shown
that Bacille Calmette-Guerin (BCG) vaccination and
measles vaccination have strong beneficial effect on child
survival [14-16]. It is also known that a substantial part
of the mortality due to malaria is not directly attributable
to malaria (i.e., indirectly attributed to malaria) [17] and
results of adequately executed malaria control or elimina-
tion programmes could exceed expectations due to
decreased indirect malaria mortality [18-20]. Malaria
infections may alter the capacity to survive other affec-
tions for example through chronic anaemia and enhance-
ment of the severity of other childhood diseases.
IPTi has now been adopted by the WHO as a policy
for malaria control despite the lack of data on the
impact of the strategy on mortality [5,21,22].
This study has two major strengths. First, it is a ran-
domized controlled study, which ensures the compar-
ability between the two arms. Second, the IPTi was
implemented within the health care system, better
reflecting the environment in which the strategy will be
Table 1 Mortality rates, mortality rates ratios and reductions in mortality in the two cohorts in the intervention and
non-intervention zone
Cohort 1 (4-18 months of age) Cohort 2 (4-12 months of age)
IPTi-SP Control IPTi-SP Control
Death 86 112 51 68
Person-days 1,018,825 971,905 688,294 652,688
Mortality rate per 1000 children 2.532 3.456 2.223 3.126
Unadjusted RR (95% IC) 0.73 (0.55-0.98) 0.71 (0.48-1.04)
p 0.030 0.066
Adjusted* RR (IC 95%) in Cox model 0.73 (0.55-0.97) 0.71 (0.49-1.02)
p* (two-sided) 0.029 0.064
Reduction in mortality* (%) 27 (3-45) 29 (0-49)
* adjusted for gender in Cox model
ĚĂǇƐ
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Figure 1 Kaplan Meir survival estimates of time to death from age of four months in the two zones.
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viduals not involved in the implementation and who
were not aware if a locality was in the intervention or
non-intervention zone, it is difficult to rule out the pos-
sibility of observer bias, since it would be easy to find
out if a locality was in the intervention or non interven-
tion zone. The mortality rateo b s e r v e di nt h ep r e s e n t
study was lower than expected (40.8 per 1,000 in the
non-intervention zone compared to 106 per 1,000 at the
national level according to the national health survey)
resulting in relatively lower power and wider confidence
intervals. Reassuringly, the mortality rates in this study
are consistent with those reported elsewhere in the
West African region [14,23,24]. Another limitation of
the study is the relatively shorter period of the interven-
tion (two years). It is possible that the impact of the
strategy on the mortality increases with the duration of
the intervention (for example, reduction in the malaria
parasite carriage leading to a reduction in the transmis-
sion). It is therefore important that the impact of the
implementation of the strategy continue to be moni-
tored over longer periods of time during the implemen-
tation of the strategy as policy.
Conclusion
The implementation of the IPTi has resulted in a 27%
reduction of the all-cause mortality in children aged
four to 18 months. The results of this study support the
adoption of IPTi as malaria control strategy and its
implementation as a tool for malaria control.
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